(4-甲氧基苯基氨基)-乙酸肼 | 79476-73-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (4-甲氧基苯基氨基)-乙酸肼
• 英文名称: 2-((4-methoxyphenyl)amino)acetohydrazide
• 英文别名: 2-(4-methoxyphenylamino)acetohydrazide；N-(4-methoxy-phenyl)-glycine hydrazide；N-(4-Methoxy-phenyl)-glycin-hydrazid；N-<4-Methoxyphenyl>-glycinhydrazid；2-(4-Methoxyanilino)acetohydrazide
• CAS: 79476-73-6
• 化学式: C₉H₁₃N₃O₂
• mdl: MFCD00462929
• 分子量: 195.221
• InChiKey: IVOFQEDOJHLXNJ-UHFFFAOYSA-N

物化性质

• 熔点：
  117 °C
• 沸点：
  468.3±30.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (4-Methoxy-phenylamino)-acetic acid hydrazide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (4-Methoxy-phenylamino)-acetic acid hydrazide
CAS number: 79476-73-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H13N3O2
Molecular weight: 195.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-甲氧基苯基氨基)-乙酸肼 在 硫酸 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 32.0h， 生成 N'1-(2-((4-methoxyphenyl)amino)acetyl)-N'4-((2S,3R,4R)-2,3,4,5-tetra-hydroxypentylidene)succinohydrazide
  参考文献：
  名称：

  新型N-(芳基甘氨酰)琥珀酰肼及其糖腙衍生物的合成及细胞毒活性

  摘要：

  DOI：

  10.21608/ejchem.2021.106807.4902
• 作为产物：
  描述：

  2-(4-甲氧基苯基氨基)乙酸乙酯 在 肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 (4-甲氧基苯基氨基)-乙酸肼
  参考文献：
  名称：

  N'-（呋喃-3-基亚甲基）-2-（4-甲氧基苯基氨基）乙酰肼的钴（II），镍（II），铜（II），锌（II）和ha（IV）络合物。

  摘要：

  合成了呋喃-2-甲醛4-甲氧基-N-苯胺基乙酰hydr的钴（II），镍（II），铜（II），锌（II）和ha（IV）配合物，并通过元素和热（TG和DTA）表征）分析，IR，UV-vis和（1）H NMR光谱以及磁矩和摩尔电导率。以1∶1的摩尔比获得单核配合物，除了以1∶2的摩尔比获得的配合物3和9。配体和金属配合物的红外光谱揭示了各种螯合模式。配体表现为中性的二齿配体，并且通过羰基氧原子和偶氮甲碱氮原子发生配位。配体也表现为一元三齿之一，并且通过烯醇式氧原子，偶氮甲碱氮原子和呋喃环的氧原子发生配位。此外，配体表现为中性三齿，并通过羰基氧，偶氮甲碱氮和呋喃氧原子以及一元二齿发生配位，并且通过烯醇式氧原子和偶氮甲氮氮原子发生配位。电子光谱和磁矩测量表明，除了铜配合物10具有正方形平面几何形状以外，所有配合物均具有八面体几何形状。热学研究表明，金属络合物中涉及的水分子类型以及某些金属络合物的热分

  DOI：

  10.1016/j.saa.2008.09.015

文献信息

• Synthesis and Antiviral Evaluation of Some Sugar Arylglycinoylhydrazones and Their Oxadiazoline Derivatives
  作者：Mohammed T. Abdel-Aal、Wael A. El-Sayed、El-Sayed H. El-Ashry

  DOI：10.1002/ardp.200600100

  日期：2006.12

  Sugar N‐arylaminoacetylhydrazones 2–5 were prepared by the reaction of N‐arylaminoacetylhydrazides 1 with equivalent amounts of the corresponding monosaccharides. Per‐O‐acetyl derivatives 6‐9 of sugar hydrazones 2–5 were prepared by using acetic anhydride in pyridine at room temperature, while on boiling with acetic anhydride, cyclization had taken place to give the oxadiazolines 10–12. The prepared

  糖 N-芳基氨基乙酰基腙 2-5 是通过 N-芳基氨基乙酰基酰肼 1 与等量的相应单糖反应制备的。在室温下在吡啶中使用乙酸酐制备糖腙2-5的过-O-乙酰基衍生物6-9，在与乙酸酐一起沸腾时，发生环化反应得到恶二唑啉10-12。测试制备的化合物对 1 型单纯疱疹病毒 (HSV-1) 和甲型肝炎病毒 (HAV、MBB 细胞培养适应株) 的抗病毒活性。噬斑减少感染性测定用于确定由于用测试化合物处理而导致的病毒计数减少。
• [EN] USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO)<br/>[FR] UTILISATION DE DERIVES DE 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONES COMME INHIBITEURS DE L'ENZYME MYELOPEROXYDASE (MPO)
  申请人：ASTRAZENECA AB

  公开号：WO2004096781A1

  公开（公告）日：2004-11-11

  There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

  揭示了使用公式(I)中X、Y、W和Q如规范中定义的化合物及其药用盐，在制造药物中用于治疗或预防对髓过氧化物酶（MPO）抑制有益的疾病或症状。公开了某些公式(I)的新化合物及其药用盐，以及它们的制备方法。公式(I)的化合物是MPO抑制剂，因此在治疗或预防神经炎症性疾病中特别有用。
• Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
  作者：Tomohiro Okawa、Yoshio Aramaki、Mitsuo Yamamoto、Toshitake Kobayashi、Shoji Fukumoto、Yukio Toyoda、Tsutomu Henta、Akito Hata、Shota Ikeda、Manami Kaneko、Isaac D. Hoffman、Bi-Ching Sang、Hua Zou、Tetsuji Kawamoto

  DOI：10.1021/acs.jmedchem.7b00443

  日期：2017.8.24

  for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2

  用于心力衰竭的一类新型治疗药物，高效和选择性的GRK2抑制剂，在体外研究中表现出增强的β-肾上腺素信号传导能力。HTS将衍生物5和1,2,4-三唑衍生物24a鉴定为命中化合物。新一代的脚手架和所有部分的SAR研究都产生了带有N-苄基羧酰胺部分的4-甲基-1,2,4-三唑衍生物，对GRK2的活性很高，对其他激酶的选择性更高。在亚型选择性方面，这些化合物对GRK1、5、6和7表现出足够的选择性，并且对GRK3具有几乎相同的抑制作用。我们的药物化学努力导致发现了115h（GRK2 IC 50= 18 nM），获得了与人GRK2和GRK2抑制剂的共晶体结构，该抑制剂增强了β-肾上腺素能受体（βAR）介导的cAMP积累，并防止了用异丙肾上腺素处理过的表达β2AR的HEK293细胞中βAR的内在化。因此，115h似乎是心力衰竭治疗的一种新型疗法。
• Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
  申请人：Svensson Mats

  公开号：US20070093483A1

  公开（公告）日：2007-04-26

  There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

  本发明揭示了使用化合物(I)的使用，其中X、Y、W和Q如规范中所定义，以及其药学上可接受的盐，在制造药物方面，用于治疗或预防抑制髓过氧化物酶（MPO）酶有益的疾病或状况。揭示了某些新型化合物(I)及其药学上可接受的盐，以及其制备方法。化合物(I)的MPO抑制剂，因此特别适用于治疗或预防神经炎症性疾病。
• Syntheses and Anti-inflammatory Activities of Substituted Arylamino-(N′-benzylidene)acetohydrazides and Derivatives
  作者：Mahima Verma、Vibha R. Gujrati、Manju Sharma、Tirloki N. Bhalla、Anil K. Saxena、Jagdish N. Sinha、Krishna P. Bhargava、Kirpa Shanker

  DOI：10.1002/ardp.19843171015

  日期：——

  The substituted arylamino‐(N′‐benzylidene)acetohydrazides 1–6, substituted acetic acid arylamino‐(N′‐benzyl)acetohydrazides 7–12 and N‐(3‐chloro‐2‐oxo‐4‐phenylazetan‐1‐yl) (phenylamino)acetamides 13–16, containing a β‐lactam ring were synthesized and studied for their anti‐inflammatory activities against carrageenin induced paw oedema in albino rats. Compound 7 was most active (30.6% at 50mg/kg p.

  取代的芳氨基-(N'-苄基)乙酰肼1-6、取代的乙酸芳氨基-(N'-苄基)乙酰肼7-12和N-(3-氯-2-氧代-4-苯氮杂-1-基)合成了含有 β-内酰胺环的（苯基氨基）乙酰胺 13-16，并研究了它们对角叉菜胶诱导的白化大鼠足部水肿的抗炎活性。化合物 7 的活性最高（50mg/kg po 时为 30.6%），急性毒性最小。所有化合物均显示出显着但可变的 (44-80%) 抑制抗蛋白水解活性。